7.64
0.66%
0.05
Chromadex Corp Stock (CDXC) Latest News
ChromaDex stock soars to 52-week high, hits $7.87 - Investing.com
ChromaDex Co. (NASDAQ:CDXC) CFO Ozan Pamir Buys 2,907 Shares - MarketBeat
Chromadex CFO Pamir Ozan acquires $21,396 in company stock By Investing.com - Investing.com Australia
Chromadex CFO Pamir Ozan acquires $21,396 in company stock - Investing.com India
Insider Buying: Ozan Pamir Acquires Shares of ChromaDex Corp (CD - GuruFocus.com
ChromaDex (NASDAQ:CDXC) Trading Down 5.5%Time to Sell? - MarketBeat
ChromaDex Corporation (CDXC) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
ChromaDex updates equity offering program, adds Roth Capital Partners - Investing.com
ChromaDex updates equity offering program, adds Roth Capital Partners By Investing.com - Investing.com Nigeria
Recent Price Trend in ChromaDex (CDXC) is Your Friend, Here's Why - Yahoo Finance
ChromaDex Gears Up to Report Q3 Earnings: Here's What to Expect - MSN
ChromaDex stock soars to 52-week high, hits $7.58 By Investing.com - Investing.com Australia
ChromaDex stock soars to 52-week high, hits $7.58 - Investing.com
ChromaDex Co. (NASDAQ:CDXC) Short Interest Update - MarketBeat
ChromaDex Expands Niagen IV Access to 200+ Restore Hyper Wellness Clinics - Athletech News
, Featured as the Hero Ingredient in Longevity.Technology’s Inaugural Longevity Supplement - Business Wire
ChromaDex (NASDAQ:CDXC) Sets New 12-Month HighHere's Why - MarketBeat
ChromaDex stock soars to 52-week high, hits $7.08 - Investing.com
ChromaDex (NASDAQ:CDXC) Cut to "Buy" at StockNews.com - MarketBeat
What Makes ChromaDex (CDXC) a Strong Momentum Stock: Buy Now? - Yahoo Finance
ChromaDex rolls out Niagen IV at wellness centers By Investing.com - Investing.com Australia
What is Roth Capital's Estimate for ChromaDex Q2 Earnings? - MarketBeat
ChromaDex rolls out Niagen IV at wellness centers - Investing.com India
ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide - Business Wire
Research Analysts Issue Forecasts for ChromaDex Q4 Earnings - MarketBeat
Shareholders Can Be Confident That ChromaDex's (NASDAQ:CDXC) Earnings Are High Quality - Yahoo Finance
ChromaDex (NASDAQ:CDXC) Hits New 12-Month High After Analyst Upgrade - Defense World
HC Wainwright Issues Positive Outlook for ChromaDex Earnings - MarketBeat
ChromaDex achieves financial stability with strong earnings report, soaring stock price - Natural Products Insider
ChromaDex Corporation (CDXC) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
HC Wainwright Brokers Boost Earnings Estimates for ChromaDex - MarketBeat
ChromaDex records 31% sales growth; stock PT raised to $8 by H.C. Wainwright - Investing.com
Are Investors Keen On Selling Holdings In Chromadex Corp (NASDAQ: CDXC)? - Stocks Register
ChromaDex (NASDAQ:CDXC) Given New $8.00 Price Target at HC Wainwright - MarketBeat
BSW Wealth Partners Acquires Shares of 88,847 ChromaDex Co. (NASDAQ:CDXC) - MarketBeat
Roth Capital Estimates ChromaDex's Q2 Earnings (NASDAQ:CDXC) - MarketBeat
ChromaDex (NASDAQ:CDXC) Releases Quarterly Earnings Results - MarketBeat
ChromaDex Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
ChromaDex Corp (CDXC) Q3 2024 Earnings Call Highlights: Record R - GuruFocus.com
ChromaDex stock soars to 52-week high, hits $4.69 By Investing.com - Investing.com Nigeria
ChromaDex stock soars to 52-week high, hits $4.69 - Investing.com India
ChromaDex (CDXC) Beats Q3 Earnings and Revenue Estimates - MSN
ChromaDex Corp (CDXC) Q3 2024 Earnings: EPS of $0.02 Beats Estimates, Revenue Hits $25.6 Million - GuruFocus.com
ChromaDex Corp (CDXC) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance
ChromaDex surges on surprise Q3 profit - XM
ChromaDex: Q3 Earnings Snapshot - New Haven Register
ChromaDex Reports Strong Q3 2024 Financial Results - TipRanks
ChromaDex Corporation Reports Third Quarter 2024 Financial Results - BioSpace
ChromaDex Shares Climb on Forecast for 15% Revenue Growth - MarketWatch
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):